SELB - Selecta Biosciences Inc Stock Price, Fair Value and News

$0.84-0.01 (-1.18%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

SELB Price Action

SELB RSI Chart

SELB Valuation

Market Cap

21.3M

Price/Earnings (Trailing)

-0.09

Price/Sales (Trailing)

0.45

EV/EBITDA

0.96

Price/Free Cashflow

-0.44

SELB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

SELB Fundamentals

SELB Revenue

Revenue (TTM)

47.9M

Rev. Growth (Yr)

-94.09%

Rev. Growth (Qtr)

-98.84%

SELB Earnings

Earnings (TTM)

-244.8M

Earnings Growth (Yr)

-168.64%

Earnings Growth (Qtr)

-274.78%

SELB Profitability

EBT Margin

-434.45%

Return on Equity

-32.6K%

Return on Assets

-53.77%

Free Cashflow Yield

-226.76%

SELB Investor Care

Buy Backs (1Y)

83.62%

Diluted EPS (TTM)

-4.54

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	25.9M	54.1M	47.9M	0
2023	82.7M	48.7M	34.5M	26.0M
2022	108.0M	127.6M	123.9M	110.8M
2021	32.0M	47.3M	67.1M	85.1M
2020	9.7M	12.0M	14.3M	16.6M
2019	1.7M	1.7M	1.6M	7.4M
2018	588.3K	969.5K	1.4M	1.7M
2017	6.1M	4.1M	2.2M	207.0K
2016	7.1M	7.8M	7.3M	8.1M
2015	3.8M	4.5M	5.3M	6.0M
2014	0	0	0	3.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Selecta Biosciences Inc

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

CEO	Dr. Carsten Brunn Ph.D.
WEBSITE	https://selectabio.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	64

Selecta Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Selecta Biosciences Inc? What does SELB stand for in stocks?

SELB is the stock ticker symbol of Selecta Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Selecta Biosciences Inc (SELB)?

As of Thu Oct 31 2024, market cap of Selecta Biosciences Inc is 21.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SELB stock?

You can check SELB's fair value in chart for subscribers.

Is Selecta Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether SELB is over valued or under valued. Whether Selecta Biosciences Inc is cheap or expensive depends on the assumptions which impact Selecta Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SELB.

What is Selecta Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Oct 31 2024, SELB's PE ratio (Price to Earnings) is -0.09 and Price to Sales (PS) ratio is 0.45. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SELB PE ratio will change depending on the future growth rate expectations of investors.